Menu

For UK Healthcare Professionals

 

EFFICACY AND SAFETY

VOCABRIA + REKAMBYS Phase 3 trials

The first and only, complete long-acting injectable regimen, offering non-inferior efficacy to daily oral HIV therapy

VOCABRIA + REKAMBYS is a different way to dose HIV-1 treatment that could offer your patients freedom from daily ARV therapy with dosing once every 2-months.1

In the FLAIR and ATLAS studies, monthly VOCABRIA + REKAMBYS was demonstrated as non-inferior to daily oral therapy. In the ATLAS-2M study, every 2-month dosing was demonstrated as non-inferior to monthly VOCABRIA + REKAMBYS.1–4

These large, global studies included over 2200 subjects.1–4 They were part of a broad clinical program to show that long-acting therapy is non-inferior to currently available daily HIV treatments.1–4

The efficacy and safety of VOCABRIA + REKAMBYS was demonstrated in clinical trials, over 48 weeks

Table showing the clinical trial results of ATLAS-2M, ATLAS and FLAIR studies

Colleague Testimonials

Hear what colleagues say about their experiences with long-acting therapy

Need to discuss further?

Icon for CTA Button

Contact us

*HIV-1 RNA <50 copies/mL.1-4

ARV=antiretroviral.

References:

  1. VOCABRIA Summary of Product Characteristics. ViiV Healthcare.
  2. Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112-1123.
  3. Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020; 382:1124-35. doi: 10.1056/NEJMoa1909512.
  4. Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. Published online ahead of print: December 9, 2020. doi: 10.1016/S0140-6736(20)32666-0.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

REKAMBYS (rilpivirine long acting injection), including the trademark is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.

PM-GB-CBR-WCNT-210001v3 I April 2022

Prescribing Information

Report an adverse event

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.